  We assessed the predictive value of new radiomic features characterizing the
lesion dissemination in baseline 18F-FDG PET and tested whether combining them
with baseline metabolic tumour volume (MTV) could improve prediction of
progression free survival (PFS) and overall survival (OS) in diffuse large B
cell lymphoma (DLBCL) patients.
